Evidence map›Paper›PMID 19019207›Full record

ArticleBreast cancer research : BCR2008

ErbB3 is required for ductal morphogenesis in the mouse mammary gland.

Amy J Jackson-Fisher, Gary Bellinger, Jerrica L Breindel, Fatteneh A Tavassoli, Carmen J Booth, James K Duong, David F Stern

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 51 citations in OpenAlex.

  1. Article
  2. Embryonic Mammary Gland Morphogenesis.Advances in experimental medicine and biology · 2025
    Review
  3. Article
  4. Review
  5. Review
  6. Busting the Breast Cancer with AstraZeneca's Gefitinib.Advances in pharmacological and pharmaceutical sciences · 2023
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Amy J Jackson-FisherDepartment of Pathology, Yale School of Medicine, New Haven, CT 06520-8023, USA.
Gary Bellinger
Jerrica L Breindel
Fatteneh A Tavassoli
Carmen J Booth
James K Duong
David F Stern
Yale University · USColumbia University · USPfizer (United States) · US

Funding

TRANSFORMATION BY THE NEU ONCOGENE PRODUCT AND EGFR01CA045708 · NCI · YALE UNIVERSITY · PI STERN, DAVID F · 1987 to 2011
$3.8M
NCI NIH HHS R01 CA045708NCI NIH HHS R01CA45708
6 · The paper itself

Abstract

introductionThe receptor ErbB3/HER3 is often over-expressed in human breast cancers, frequently in conjunction with over-expression of the proto-oncogene ERBB2/HER2/NEU. Although the prognostic/predictive value of ErbB3 expression in breast cancer is unclear, ErbB3 is known to contribute to therapeutic resistance. Understanding ErbB3 functions in the normal mammary gland will help to explain its role in cancer etiology and as a modulator of signaling responses to the mammary oncogene ERBB2.

methodsTo investigate the roles of ErbB3 in mouse mammary gland development, we transplanted mammary buds from ErbB3-/- embryos into the cleared mammary fat pads of wild-type immunocompromised mice. Effects on ductal outgrowth were analyzed at 4 weeks, 7 weeks and 20 weeks after transplantation for total ductal outgrowth, branch density, and number and area of terminal end buds. Sections of glands containing terminal end buds were analyzed for number and epithelial area of terminal end buds. Terminal end buds were also analyzed for presence of mitotic figures, apoptotic figures, BrdU incorporation, and expression of E-cadherin, P-cadherin, alpha-smooth muscle actin, and cleaved caspase-3.

resultsThe mammary ductal trees developed from ErbB3-/- buds only partly filled the mammary fat pad. In contrast to similar experiments with ErbB2-/- mammary buds, this phenotype was maintained through adulthood, pregnancy, and parturition. In addition, and in contrast to similar work with ErbB4-/- mammary buds, lobuloalveolar development of ErbB3-/- transplanted glands was normal. The ErbB3-/- mammary outgrowth defect was associated with a decrease in the size of the terminal end buds, and with increases in branch density, in the number of terminal end buds, and in the number of luminal spaces. Proliferation rates were not affected by the lack of ErbB3, but there was an increase in apoptosis in ErbB3-/- terminal end buds.

conclusionsEndogenous ErbB3 regulates morphogenesis of mammary epithelium.

Indexed as

MorphogenesisActinsAnimalsApoptosisBromodeoxyuridineCadherinsCaspase 3Cell ProliferationEpitheliumFemaleMammary Glands, AnimalMiceMice, Inbred BALB CMice, Inbred C57BLMice, KnockoutMuscle, SmoothActinsBromodeoxyuridineCadherinsCasp3 protein, mouseCaspase 3MAS1 protein, humanProto-Oncogene MasReceptor, ErbB-3

Identifiers

PMID19019207
PMCPMC2656891
OpenAlexW1996735618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.